BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23728739)

  • 1. Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.
    Jin HJ; Zhang H; Sun ML; Zhang BG; Zhang JW
    J Thromb Thrombolysis; 2013 Nov; 36(4):458-68. PubMed ID: 23728739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis based on magnetically-controlled surface-functionalized Fe
    Chang M; Lin YH; Gabayno JL; Li Q; Liu X
    Bioengineered; 2017 Jan; 8(1):29-35. PubMed ID: 27689864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catheter-based local thrombolysis with urokinase: comparative efficacy of intraluminal clot lysis with conventional urokinase infusion techniques in an in vivo porcine thrombus model.
    Mitchel JF; Shwedick M; Alberghini TA; Knibbs D; McKay RG
    Cathet Cardiovasc Diagn; 1997 Jul; 41(3):293-302. PubMed ID: 9213028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
    Bagre AP; Jain K; Jain NK
    Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermia-triggered UK release nanovectors for deep venous thrombosis therapy.
    Xu J; Zhou Y; Nie H; Xiong Z; OuYang H; Huang L; Fang H; Jiang H; Huang F; Yang Y; Ding X; Wang X; Zhou W
    J Mater Chem B; 2020 Jan; 8(4):787-793. PubMed ID: 31899460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for non-acute deep venous thrombosis of the lower extremity.
    Gao B; Zhang J; Wu X; Han Z; Zhou H; Dong D; Jin X
    Korean J Radiol; 2011; 12(1):97-106. PubMed ID: 21228945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
    Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
    Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
    Chung TW; Wang SS; Tsai WJ
    Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy versus thrombolysis alone in upper and lower extremity deep vein thrombosis.
    Kim HS; Patra A; Paxton BE; Khan J; Streiff MB
    Cardiovasc Intervent Radiol; 2006; 29(6):1003-7. PubMed ID: 16967220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catheter-directed thrombolysis through anterior tibial vein for treating acute extensive deep venous thrombosis.
    Wang H; Qi X; Luo H; Zhang Q; Chen Y; Sun J
    J Vasc Surg Venous Lymphat Disord; 2018 Nov; 6(6):681-688. PubMed ID: 30126796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and Properties of Thrombus-Targeted Urokinase/Multi-Walled Carbon Nanotubes (MWCNTs)-Chitosan (CS)-RGD Drug Delivery System.
    Zhang R; Luo S; Hao LK; Jiang YY; Gao Y; Zhang NN; Zhang XC; Song YM
    J Biomed Nanotechnol; 2021 Sep; 17(9):1711-1725. PubMed ID: 34688316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study.
    Wang SS; Chou NK; Chung TW
    J Biomed Mater Res A; 2009 Dec; 91(3):753-61. PubMed ID: 19051299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound-triggered thrombolysis using urokinase-loaded nanogels.
    Jin H; Tan H; Zhao L; Sun W; Zhu L; Sun Y; Hao H; Xing H; Liu L; Qu X; Huang Y; Yang Z
    Int J Pharm; 2012 Sep; 434(1-2):384-90. PubMed ID: 22683455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent pneumatic compression of the foot and calf improves the outcome of catheter-directed thrombolysis using low-dose urokinase in patients with acute proximal venous thrombosis of the leg.
    Ogawa T; Hoshino S; Midorikawa H; Sato K
    J Vasc Surg; 2005 Nov; 42(5):940-4. PubMed ID: 16275451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.
    Ouriel K; Gray B; Clair DG; Olin J
    J Vasc Interv Radiol; 2000 Mar; 11(3):295-8. PubMed ID: 10735422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-Targeting Glycol Chitosan/Heparin-Decorated Polypyrrole Nanoparticle for Augmented Photothermal Thrombolytic Therapy.
    Lu TY; Chiang CY; Fan YJ; Jheng PR; QuiƱones ED; Liu KT; Kuo SH; Hsieh HY; Tseng CL; Yu J; Chuang EY
    ACS Appl Mater Interfaces; 2021 Mar; 13(8):10287-10300. PubMed ID: 33615773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.
    Mitchel JF; Azrin MA; Fram DB; Hong MK; Wong SC; Barry JJ; Bow LM; Curley TM; Kiernan FJ; Waters DD
    Circulation; 1994 Oct; 90(4):1979-88. PubMed ID: 7923688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.